The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients

Julie A. Scharfstein, A. David Paltiel and Kenneth A. Freedberg

Medical Decision Making, 1997, vol. 17, issue 4, 373-381

Abstract: Objective. To project the cost-effectiveness of fluconazole for prophylaxis against AIDS-related primary systemic fungal infections. Design. A Markov model with data from the literature. Patients. Hypothetical cohort of 100,000 AIDS patients. Intervention. No prophylaxis, and fluconazole prophylaxis beginning when a patient's CD4 count declined to below 200/mm 3 , below 100/mm 3 , or below 50/mm 3 . Results. The no-pro phylaxis policy was associated with a discounted life expectancy of 28.20 months and direct medical costs of $36,100 per person. The

Date: 1997
References: View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X9701700402 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:17:y:1997:i:4:p:373-381

DOI: 10.1177/0272989X9701700402

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().